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A Nonlinear Dosimetric Model for
Hemoglobin Adduct Formation by the
Neurotoxic Agent Acrylamide and Its
Genotoxic Metabolite Glycidamide
by Carl Johan Calleman,' Emma Bergmark,' Louis G.
Stern,2 and Lucio G. Costa'
Hemoglobin(Hb)adducts, formedbytheneurotoxic agentacrylamide (AA)anditsgenotoxicmetaboliteglycidamide
(GA), weremeasured inthe ratby meansofamethodforsimultaneousdeterminationoftheadductsformedtocysteine.
Anovel, nonlineardosimetricmodel wasdevelopedtodescribeHbadductfomation.Thismodelincorporatesthesaturable
kinetics ofthe metabolic conversion in viwoofAA to GA. The pharmacokinetic parameters V...X andKm and the first-
order ratesofelimination, k, andk2, forAAandGAfromall processesexceptconversionofAAtoGA, wereestimated
directly from Hbadduct data to 19Mhri", 66 AM, 0.21 hr1, andOA8hr', respectively. Atlowconcentrations, approx-
imately60%ofAAwasmetabolized toGA. Thenonlineardosimetric modelforadductformation haspotentialgeneral
applicability in high-to-low-dose extrapolation ofgenotoxic effects.
The development ofanalytical methods for quantitating ad-
ducts formedbyelectrophilic substances withmacromolecules
such as hemoglobin (Hb) and DNA has made significant pro-
gressoverthepastdecades, andsuchadductshavebeenproposed
as biomarkers for use in epidemiological studies aiming to
monitor human exposure to toxic agents. In contrast, mathe-
matical models foradductformation, crucial fortheuseofthese
biomarkers forhuman riskestimation, havebeenrelatively un-
sophisticated and essentially limited to the linear model. Our
work with Hb adduct formation by the neurotoxic agent
acrylamide (AA) anditsgenotoxicmetaboliteglycidamide (GA)
prompted ustodevelop anonlinearmathematical model forad-
duct formation applicable also at the high exposures where
capacity-limited processes come intoplay and toxic effects are
commonly observed in experimental organisms.
Humans areexposed toAA mainly inthechemical industry,
molecular biology laboratories, and grouting operations (1).
Acrylamidehas for a long timebeen known tobeneurotoxic in
animals and man, and more recently its genotoxic and cancer-
initiating propertieshaveattracted increasingattention. Despite
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thefactthatAA iscarcinogenicinmicewhenfollowedby treat-
ment with phorbol esters and is mutagenic in mammalian
organisms, itisnegativeintheAmestestboth intheabsenceand
inthepresenceofS9mix. Althoughepidemiologicalstudieshave
notdemonstrated increased ratesoftumorsinexposedworkers,
it is classified by the International Agency for Research on
Cancer as a possible human carcinogen based on animal
bioassays in the mouse and in the rat (2).
BecausehumanexposuretoAA inmostoccupational settings
isbelieved tooccurthrough acombinationofdermalandinhala-
tional routes (1), there is a need for a biomarker ofexposure,
suchasHbadducts, thatisindicativeofthetotal exposure. Initial
workontheuseofadductsformedbycysteineresidues inHbas
biomarkers forAAexposure wasperformedbyBaileyetal. (3),
whodevelopedamassfragmentographictechniquetodetermine
such adducts in rats given 0-5 mg AA/kg body weight. In this
rangeofconcentrations, Hbadductformation wasfound tobea
convex function ofthe injected concentration.
This unusual nonlinearrelationshipbetween Hb adduct for-
mation and injected concentration, as well as several studies
showinganimpactofphenobarbital induction onthe neurotox-
icity ofAA in rats, indicated to us that AA underwent further
metabolism in acytochrome P-450-mediated reaction. Inanat-
tempttoconfirmthehypothesis that AA wasmetabolically ox-
idizedtotheepoxideGA, weanalyzedHbhydrolysatesfromrats
treated with AA and were able to identify S-(2-carboxy-
2-hydroxyethyl)-cysteine, the adduct formed by GA, by means
ofGC-MS (4) (Fig. 1).CALLEMANETAL.
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In contrast, adduct formation by either AA or its metabolite
GA in rats treated with an initial concentration, [AA]o, ofAA in
therange0-100mg/kgbodyweightwas inconsistentwithalinear
model. Thus, whileadductformationby AA wasconvex (3), ap-
proaching linearity athigh concentrations, adductformation by
° GA was a concave function ofthe injected concentration, pre-
sumably reflectinga saturableMichaelis-Menten typeofkinetics
forthemetabolicconversionofAAto GA. Thefollowingkinetic
scenarios for AA and GA, respectively, were thus assumed:
d[AAI = kl[AA] + KVmax [AA]
dt(K [A ]
(3)
and
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FIGURE 1. Scheme of formation and derivatization of hemoglobin adducts
formed by acrylamide and glycidamide.
To evaluate the role of GA in the induction oftoxic effects
associated with AA exposure, aseriesofexperiments was under-
taken to study its toxicological properties and quantitative
relevance as a metabolite. It was thus found that AA itselfwas
primarily responsible forcausing peripheral neuropathy asjudg-
ed from the inability ofGA to cause neuropathological damage
to sciatic nerves or have an effect in the hindlimb splay test in
treated animals (5, Deng et al., in preparation). On the other
hand, GAhadastrong impactonbodyweight, spermcellviabili-
ty, andepididymal daily spermproduction in malerats (5), im-
plicating a roleofGA in the inductionofmale reproductive tox-
icity in rodents given AA. Already prior to its discovery as a
metaboliteofAA, GAhadbeen showntogiveapositive response
in the Ames test (6). It was thus hypothesized (4) that GA was
the agent responsible for the cancer-initiating properties as-
sociated with AA exposure in experimental animals.
To be ableto measure tissue doses (7), DAA and DGA, ofboth
AA and GA, for risk assessment of neurotoxic (DAA) or re-
productive and genotoxic effects (DGA), respectively, we de-
veloped a GC-MS technique that allows us to simultaneously
determine Hbadducts to cysteine formed by both electrophiles
(8) (Fig. 1). Using this techique, the concentration ofadducts
formed byGA-(GAHb) inrats wasfoundtobelinearlydependent
on the injected concentration ofGA ([GA]O) and k*GA, the rate
ofelimination ofGA fromtheblood, was estimated to0.48 hr'
from Equations 1 and 2 [cf. Osterman-Golkar et al.(7)]
00
DGA= J[GA] =b1[GAHBI
0 ]kHb~[Hb]
(1)
and 00
DGA=f|GA]dt.= [GA]o ek*GAtdt= - * (2) 0 0 kGA (2
Equation 2 is derived from a linear kinetic scenario:
-(d[GA]/dt) = k*GA [GA], applicable when [GA] < <Ki,
where rates forsaturable processes following Michaelis-Menten
kinetics are approximated by Vmax/Km and lumped together in
the constant k*GA.
in which Vmax and Km aretheparameters forthe metabolic con-
versionofAAtoGAandk, andk2arethe ratesofelimination of
AAandGAfromallotherprocesses. Todescribe Hbadductfor-
mationby AAandGA inthis scenario, thedifferential Equations
3 and4 weresolvedby atransformation ofvariablesand integra-
tion oftheir sum (Calleman et al., in preparation) to yield the
expressions:
DAA=L([AA]o- Vmax [n (I + AA]
klklIn(1+ (Vmax/kl + )
(5)
and Vm=ax [AA+ DGA=k lii (1 + (Vmax/ki + Kin)
(6)
Thevaluesofthepharmacokinetic parameters givingthebest
fit to the observed values for Hb adduct formation were 19AM
hr-', 66 AM, 0.21 hr', and 0.48 hr' for Vmax Ki k1, and k2,
respectively (Fig. 2). At low concentrations ofsubstrate, where
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FIGURE 2. Tissue doses of acrylamide (AA) and glycidamide (GA) in rats
treated with AA: Equations 5 and 6, with parametrical values inserted for
Vmax, Km, k,, and k2, describing thetissuedoses, DAA and DGA(kM/hr), as
functionsofthe initial concentrationofAA (mg/kg body weight) in rats. The
datapoints for tissue doses DAA (-)and DGA(*) were calculated from ex-
perimentally determinedconcentrations ofhemoglobinadductsaccordingto
Equation 1.
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alinear model isapplicable, k*AA = (k, + Vmax/Km) = 0.21 hr-'
+ (19 ttM hr 1/66 sM) 0.50hr1' for AA ingoodagreement with
the value 0.40 hr", determined by Miller et al. (9) from direct
measurements ofthe concentration ofAA in the blood ofrats.
TheproportionofAAmetabolically converted toGAincreases
as [AAJO decreases and approaches (Vmax/Km)/k*AA = 0.58 at
very low values.
Equations5and 6describe tissuedoses and arethuspropor-
tional to Hbadductformation(Equation 1)byaparentcompound
orametabolite, respectively, undergoingasaturableprocess. As
capacity-limited processes arecommonplace inthemetabolism
oftoxic agentsandEquations Sand6areusefulalso formodel-
ing DNAadductformation, theymeritconsideration forincor-
poration intogeneral models forhigh-to-low-doseextrapolation
ofrisks associated with exposure togenotoxic/cancer-initiating
agents.
In summary, we have developed amethod to simultaneously
determine Hb adduct formation by AA and its genotoxic me-
taboliteGA intreated rats. Basedontheobservednonlinearities
inthe Hbadductformation bythetwoagents, wehavedeveloped
anovel mathematical model (10) thatdescribes adductformation
in vivobyagentsundergoing saturablemetabolicprocessesand
is potentially useful for high-to-low-dose extrapolation of
genotoxiceffects. Bymeansofthismodelthevaluesofthephar-
macokinetic parameters Vmax, Kin, k,, andk2 wereestimated in
the rat. Studies are now under way todetermine Hb adducts by
AA and GA in humans exposed to AA industrially and in
molecularbiology laboratories asabasis foraquantitative risk
estimation ofthis substance.
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